OSCAR HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.56 USD | -1.84% |
|
+9.68% | +91.91% |
| Mar. 22 | Raymond James Starts Oscar Health With Outperform Rating, $20 Price Target | MT |
| Mar. 18 | Oscar Health, Inc.(NYSE:OSCR) added to S&P Insurance Select Industry Index | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,645 | 528.3 | 2,066 | 4,156 | - | - |
| Enterprise Value (EV) 1 | 540.7 | -732.3 | 494.5 | 2,074 | 1,495 | 838.4 |
| P/E ratio | -2.45 x | -0.86 x | -7.5 x | -97.6 x | 41.8 x | 16 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.61 x | 0.1 x | 0.35 x | 0.5 x | 0.41 x | 0.35 x |
| EV / Revenue | 0.2 x | -0.14 x | 0.08 x | 0.25 x | 0.15 x | 0.07 x |
| EV / EBITDA | -1.26 x | 1.58 x | -10.9 x | 12.2 x | 4.63 x | 1.68 x |
| EV / FCF | - | - | -1.66 x | 1.28 x | 2.31 x | 1.01 x |
| FCF Yield | - | - | -60.2% | 78.1% | 43.3% | 98.5% |
| Price to Book | 0.99 x | 0.6 x | - | - | - | - |
| Nbr of stocks (in thousands) | 209,516 | 214,755 | 225,797 | 236,666 | - | - |
| Reference price 2 | 7.850 | 2.460 | 9.150 | 17.56 | 17.56 | 17.56 |
| Announcement Date | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,648 | 2,713 | 5,335 | 5,865 | 8,377 | 10,171 | 11,822 |
| EBITDA 1 | - | -429.8 | -462.3 | -45.24 | 169.8 | 322.9 | 499.8 |
| EBIT 1 | - | -544.5 | -589.9 | -235.6 | 76.19 | 232.6 | 254.6 |
| Operating Margin | - | -20.07% | -11.06% | -4.02% | 0.91% | 2.29% | 2.15% |
| Earnings before Tax (EBT) 1 | - | -570.6 | -610.1 | -267.3 | -25.78 | 127.4 | 290.1 |
| Net income 1 | - | -572.6 | -606.3 | -270.7 | -25.77 | 118.9 | 265.1 |
| Net margin | - | -21.11% | -11.37% | -4.62% | -0.31% | 1.17% | 2.24% |
| EPS 2 | -4.720 | -3.200 | -2.850 | -1.220 | -0.1800 | 0.4200 | 1.095 |
| Free Cash Flow 1 | - | - | - | -297.7 | 1,620 | 647.1 | 826 |
| FCF margin | - | - | - | -5.08% | 19.34% | 6.36% | 6.99% |
| FCF Conversion (EBITDA) | - | - | - | - | 954.05% | 200.41% | 165.27% |
| FCF Conversion (Net income) | - | - | - | - | - | 544.4% | 311.63% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 2/5/21 | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 668.4 | 705.5 | 1,324 | 1,368 | 1,309 | 1,333 | 1,463 | 1,529 | 1,441 | 1,432 | 1,993 | 2,200 | 2,120 | 2,064 | 2,442 |
| EBITDA 1 | -188.7 | -164 | -37.04 | -75.8 | -160 | -189.7 | 51.07 | 35.57 | -20.28 | -111.6 | 126.4 | 96.71 | 12.79 | -65.74 | 181.9 |
| EBIT 1 | -212.9 | -196.3 | -68.53 | -106.5 | -192.4 | -222.5 | -25.36 | -6.529 | -58.24 | -145.5 | 103.2 | 77.14 | -7.967 | -96.23 | - |
| Operating Margin | -31.86% | -27.82% | -5.17% | -7.78% | -14.69% | -16.69% | -1.73% | -0.43% | -4.04% | -10.16% | 5.18% | 3.51% | -0.38% | -4.66% | - |
| Earnings before Tax (EBT) 1 | -213.3 | -197.9 | - | -111.8 | -195.2 | - | - | - | -64.79 | -150.6 | 64.55 | 41.95 | -41.7 | -115.8 | 125.3 |
| Net income 1 | -212.7 | -198.9 | -75.15 | -112.2 | -192.9 | -226 | -39.77 | -15.53 | -65.4 | -150 | 74.45 | 46.07 | -35.74 | -114.2 | 112.3 |
| Net margin | -31.83% | -28.2% | -5.67% | -8.2% | -14.73% | -16.96% | -2.72% | -1.02% | -4.54% | -10.48% | 3.74% | 2.09% | -1.69% | -5.53% | 4.6% |
| EPS 2 | -1.020 | -0.9500 | -0.3600 | -0.5300 | -0.9100 | -1.050 | -0.1800 | -0.0700 | -0.2900 | -0.6600 | 0.2567 | 0.1633 | -0.1433 | -0.4533 | 0.4300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/10/22 | 5/10/22 | 8/11/22 | 11/8/22 | 2/9/23 | 5/9/23 | 8/8/23 | 11/7/23 | 2/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,104 | 1,261 | 1,572 | 2,081 | 2,661 | 3,318 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -298 | 1,620 | 647 | 826 |
| ROE (net income / shareholders' equity) | - | -77.5% | -53.2% | -32% | -4.53% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | 7.920 | 4.120 | - | - | - | - |
| Cash Flow per Share 2 | - | -1.020 | 1.790 | -1.230 | 0.7100 | 1.310 | - |
| Capex 1 | - | 25.9 | 29 | 25.6 | 34 | 41 | 47.5 |
| Capex / Sales | - | 0.95% | 0.54% | 0.44% | 0.41% | 0.4% | 0.4% |
| Announcement Date | 2/5/21 | 2/10/22 | 2/9/23 | 2/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.56
USD
Average target price
19
USD
Spread / Average Target
+8.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +91.91% | 4.16B | |
| +13.21% | 9.63B | |
| +16.74% | 6.08B | |
| -1.08% | 2.31B | |
| -20.94% | 1.01B | |
| +2.18% | 862M | |
| +85.42% | 748M | |
| +7.80% | 162M | |
| -8.15% | 68.79M |
- Stock Market
- Equities
- OSCR Stock
- Financials Oscar Health, Inc.
